This company has been acquired
PRVB Stock Overview
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Provention Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.98 |
| 52 Week High | US$25.00 |
| 52 Week Low | US$3.19 |
| Beta | 2.46 |
| 1 Month Change | 3.22% |
| 3 Month Change | 184.83% |
| 1 Year Change | 456.35% |
| 3 Year Change | 133.02% |
| 5 Year Change | n/a |
| Change since IPO | 419.33% |
Recent News & Updates
Recent updates
Provention Bio appoints O'Brien as Chief People Officer
Sep 19Provention Bio secures $125M term loan facility
Sep 01Provention Bio: More Risk, More Dilution Ahead - Downgrading To A Sell Rating
Aug 12Provention Bio Q2 2022 Earnings Preview
Aug 03Provention Bio to raise $60M through private placement of securities
Jul 08Provention Bio says FDA extends review period for co's teplizumab application to Nov. 17
Jun 30Provention Bio (PRVB): BLA Accepted; Downgrading To A Hold
Mar 31Provention Bio: Upgrading To A Strong-Buy, Potential Cure For Type 1 Diabetes
Feb 04Is Provention Bio (NASDAQ:PRVB) In A Good Position To Invest In Growth?
Jan 11
Is Provention Bio (NASDAQ:PRVB) In A Good Position To Deliver On Growth Plans?
Aug 26Provention Bio: Blood (Glucose) In The Streets
Jul 30FDA Advisory Committee supports Provention Bio's teplizumab in delaying diabetes
May 28Provention Bio EPS misses by $0.05
May 06Provention Bio provides regulatory update on teplizumab BLA
Apr 27How Much Of Provention Bio, Inc. (NASDAQ:PRVB) Do Insiders Own?
Mar 17Need To Know: Provention Bio, Inc. (NASDAQ:PRVB) Insiders Have Been Buying Shares
Feb 10
Provention Bio prices $100M stock offering
Jan 14Provention Bio Could See Meaningful Upside Once Teplizumab Hits The Market
Jan 07Provention Bio (NASDAQ:PRVB) Is In A Good Position To Deliver On Growth Plans
Jan 06Provention Bio files US application for its diabetes drug
Jan 04Provention Bio launches first-in-human PRV-101 study in coxsackievirus B
Dec 15Is Provention Bio, Inc.'s (NASDAQ:PRVB) Shareholder Ownership Skewed Towards Insiders?
Dec 02Provention Bio EPS misses by $0.14
Nov 05Shareholder Returns
| PRVB | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.7% | -3.2% | -3.5% |
| 1Y | 456.3% | 11.7% | 20.2% |
Return vs Industry: PRVB exceeded the US Pharmaceuticals industry which returned -0.1% over the past year.
Return vs Market: PRVB exceeded the US Market which returned -5.3% over the past year.
Price Volatility
| PRVB volatility | |
|---|---|
| PRVB Average Weekly Movement | 74.7% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PRVB's share price has been volatile over the past 3 months.
Volatility Over Time: PRVB's weekly volatility has increased from 39% to 75% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 174 | Ashleigh Palmer | www.proventionbio.com |
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Provention Bio, Inc. Fundamentals Summary
| PRVB fundamental statistics | |
|---|---|
| Market cap | US$2.37b |
| Earnings (TTM) | -US$113.56m |
| Revenue (TTM) | US$12.90m |
183.6x
P/S Ratio-20.8x
P/E RatioIs PRVB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRVB income statement (TTM) | |
|---|---|
| Revenue | US$12.90m |
| Cost of Revenue | US$76.32m |
| Gross Profit | -US$63.42m |
| Other Expenses | US$50.14m |
| Earnings | -US$113.56m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.20 |
| Gross Margin | -491.83% |
| Net Profit Margin | -880.69% |
| Debt/Equity Ratio | 19.3% |
How did PRVB perform over the long term?
See historical performance and comparison